MedPage Today on MSN

High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents

Also from SGO: p53 reactivator active in advanced gynecologic cancers, "perfect" score in ...
Seeking Alpha

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway SCLC is aggressive and ...
AOL

5 sales sequences that drive higher response rates

On average, cold emails only have a 0.9% response rate. It’s hard to stand out in a crowded inbox, and it’s only going to get harder. New email sender guidelines have been out for a couple years now.
Seeking Alpha

Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without ...
Hosted on MSN

'Mo-Rez,' a developing ovarian cancer drug, outperforms current standards with 60% response rates, offering first real hope in years

The experimental drug mocertatug rezetecan (Mo‑Rez) is showing real promise in early clinical trials for ovarian and endometrial cancers that have returned after initial treatment (recurrent), enough ...